Bevacizumab Associated With Neurodevelopmental Disabilities

Share this content:
Bevacizumab Associated With Neurodevelopmental Disabilities
Bevacizumab Associated With Neurodevelopmental Disabilities

HealthDay News -- Bevacizumab (Avastin) used to treat retinopathy of prematurity (ROP) may be linked to serious disabilities such as cerebral palsy and hearing loss, according to a study published in Pediatrics.

Julie Morin, MD, of the Sainte-Justine University Hospital Center in Montreal, and colleagues looked at 27 infants whose ROP was treated with bevacizumab, and 98 treated with laser surgery.

The researchers found that the odds of severe neurodevelopmental disabilities were 3.1 times higher in infants treated with bevacizumab versus laser, after adjustment for gestational age, gender, maternal education, Score for Neonatal Acute Physiology-II, bronchopulmonary dysplasia, sepsis, and severe brain injury.

"Preterm infants treated with bevacizumab versus laser had higher odds of severe neurodevelopmental disabilities," the authors conclude. "Further investigation on the long-term safety of antivascular endothelial growth factor treatment of ROP is needed."

Avastin manufacturer Genentech could not be reached for comment.

Reference

Morin J, Luu TM, Superstein R, et al. Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity. Pediatrics. 2016; doi:10.1542/peds.2015-3218.

You must be a registered member of Neurology Advisor to post a comment.

Sign Up for Free e-newsletters

CME Focus